In a further boost to Victoria’s mRNA and medical research advancements, mRNA Victoria will collaborate with Pfizer’s Centers for Therapeutic Innovation (CTI) and RNA Accelerator to advance critical therapeutic and vaccine research and development.
The Pfizer CTI alliance announced by the Victorian Government will build new global research networks and advance skills of Victorian researchers. Building links to Pfizer’s RNA Accelerator further strengthens Victoria’s mRNA ecosystem and underpins its leading role in medical research and innovation.
Established in 2010, Pfizer’s CTI is a unique joint drug discovery model focused on collaborating globally with academic institutions to translate and transform early discovery research into viable therapeutic products.
“This agreement with one of the world’s leading biopharmaceutical companies is a strong endorsement of the strength of Victoria’s research and development community and recognises our status as one of the world leaders in this field.” says Minister for Innovation, Medical Research and the Digital Economy Jaala Pulford
“This initiative between mRNA Victoria and Pfizer will also deliver significant job opportunities for our state as leading biotech research and commercialisation is ramped up.”
The first mRNA Victoria and Pfizer joint initiative will be a symposium to present high-impact Australian mRNA and RNA research, paving the way for greater collaborations with Pfizer’s CTI and RNA Accelerator.
Victoria is a global hub for biopharma manufacturing and this collaboration will build on existing initiatives the Victorian Government is undertaking to further develop Victoria’s strong mRNA ecosystem. Victoria is currently Australia’s leading exporter in pharmaceutical and biological manufacturing, responsible for nearly 60 per cent of Australia’s pharmaceutical exports.
Read more about mRNA Victoria and its initiatives.
Learn more about Victoria’s research and development capabilities or contact our team to explore available investment options.
